Results 181 to 190 of about 10,858 (213)

Bictegravir/emtricitabine/tenofovir-alafenamide

Reactions Weekly
  +8 more sources

Doxorubicin/tenofovir-alafenamide

Reactions Weekly, 2022
openaire   +1 more source

Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial

Lancet, The, 2013
Michael Martin, Manoj Leethochawalit, Craig W Hendrix   +2 more
exaly  

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Lancet, The, 2017
Paul E Sax, Anton L Pozniak, Andrea Antinori   +2 more
exaly  

Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults

Lancet, The, 2004
Esteban Martinez, Felipe Garcia, Jose M Gatell   +2 more
exaly  

Gentamicin/tenofovir alafenamide

Reactions Weekly, 2020
openaire   +1 more source

Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women

Science, 2010
Anneke C Grobler, Cheryl Baxter, Leila E Mansoor   +2 more
exaly  

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

New England Journal of Medicine, 2019
Willem Venter, Michelle A Moorhouse, Simiso Sokhela   +2 more
exaly  

Bictegravir/emtricitabine/tenofovir-alafenamide

Reactions Weekly, 2022
openaire   +2 more sources

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

Lancet, The, 2017
Adriano Lazzarin, Chloe Orkin, Daniel Podzamczer   +2 more
exaly